Table 1 Baseline characteristics

From: Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

Characteristic Patients ( N =26)
Age, median years (range) 60 (34–73)
Sex, n (%)
Male 16 (62)
Female 10 (38)
Race, n (%)
Caucasian 22 (85)
African American 3 (12)
Unknown 1 (4)
ECOG performance status, n (%)
0 15 (58)
1 11 (42)
Primary tumour type, n (%)
Biliary tract 6 (23)
NSCLC 3 (12)
Salivary gland 3 (12)
Bladder 2 (8)
Breast 2 (8)
Oesophagus 2 (8)
Pancreas 2 (8)
Adenocarcinoma of unknown primary 1 (4)
Othera 5 (19)
Number of prior lines of chemotherapy, n (%)
0 5 (19)
1 9 (35)
2 11 (42)
3 1 (4)
Patients with prior taxane therapy, n (%)
Paclitaxel 7 (27)
Docetaxel 2 (8)
  1. Abbreviations: ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung cancer.
  2. aOther tumour types were anal cancer, colorectal cancer, head and neck cancer, thymic carcinoma, and melanoma.